Cardiometabolic diseases may influence both risk and progression of motor neuron diseases
A new study from the Institute of Environmental Medicine (IMM), published in The Lancet Regional Health - Europe, shows that ...
ALS News Today5 小时
Corcept’s dazucorilant fails to slow ALS progression in clinical trial
Dazucorilant failed to slow disease progression in ALS patients in the DAZALS Phase 2 clinical trial, but may have extended ...
Armed robbery in Revesby4 小时
Cardiometabolic Factors Tied to Motor Neuron Diseases
A new study from the Institute of Environmental Medicine (IMM), published in The Lancet Regional Health - Europe, shows that ...
Research reveals possible link between protein G3BP1 and amyotrophic lateral sclerosis
Researchers from the Structural Biology Brussels group at Vrije Universiteit Brussel (VUB) have uncovered a significant ...
ALS News Today1 天
ROCK inhibitor Bravyl may reduce spread of TDP-43 clumps in ALS
The experimental therapy Bravyl significantly reduced the spread of toxic TDP-43 protein clumps in a cell model of ALS.
BioSpace1 天
5 Clinical Assets That Flopped in 2024
Some 90% of investigational drugs fail—and success rates are even more dire in the neuro space. Here, BioSpace looks at five ...
CMS says private Medicare plans can’t automatically deny Biogen’s ALS drug
In a rare move, the U.S. agency behind Medicare is warning Medicare Advantage providers they can’t have blanket policies that ...
Stockhead on MSN22 小时
Positive interim study results for Neurizon’s motor neuron disease drug
Neurizon has reported positive eight-month interim data from its open-label extension study in patients with ALS (motor ...
Business Wire1 天
VectorY Strengthens Leadership Team with Appointment of Jim Scibetta as New CEO
VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, announces ...